Fas/ @entity1197 ( @entity1197 ), a cell surface cytokine receptor, triggers apoptotic cell death by specific agonist antibody, suggesting that Fas/ @entity1197 may be a promising target for treatment of @entity5 . In this study, we show that treatment with anti-Fas antibody effectively induced apoptosis in @entity11 cell lines with high expression of Fas/ @entity1197 (n = 3). @entity11 cells with low or undetectable expression of Fas/ @entity1197 (n = 6), however, were resistant to Fas/ @entity1197 -dependent @entity137 . The purpose of this study, therefore, was to determine whether resistant @entity5 could be made susceptible to apoptosis. @entity23903 / @entity23903 constitutes a novel protein that associates specifically with the cytoplasmic death domain of Fas/ @entity1197 and induces apoptosis. We investigated whether overexpression of @entity23903 would induce apoptosis in @entity11 cells without activating Fas/ @entity1197 . Results indicated that about 85% of @entity11 cells, regardless of Fas/ @entity1197 expression levels, underwent apoptosis after transient transfection with @entity23903 expression vector. To further improve gene transfer of @entity23903 into @entity11 cells, we constructed a retroviral vector containing the @entity23903 gene. The retroviral transfer of @entity23903 gene significantly enhanced the transduction efficiency and effectively inhibited both in vitro and in vivo survival of @entity11 cells through induction of apoptosis. These findings suggest that the @entity23903 gene is a novel and useful tool for the treatment of @entity11 .

@entity23903 gene therapy for XXXX in vitro and in vivo.

@entity137 :: ('MESH:D064420', 'Disease') :: ['cytotoxicity'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumors'] @entity1197 :: ('355', 'Gene') :: ['CD95', 'APO-1'] @entity11 :: ('MESH:D005910', 'Disease') :: ['malignant glioma', 'malignant gliomas', 'Malignant glioma'] @entity23903 :: ('8772', 'Gene') :: ['MORT1', 'FADD']
@entity11 :: (MESH:D005910,Disease) :: ['malignant gliomas']
